Pharmacopeia, Inc. (NASDAQ: PCOP), a clinical development stage biopharmaceutical company, is focused on discovering and developing innovative small molecule therapeutics to attend to significant medical needs. The company’s broad portfolio of clinical and preclinical candidates are currently under development internally or with partners, including nine clinical compounds in Phase 2 or Phase 1 development. For further information, visit the Company’s web site at www.pcop.com.
- 17 years ago
QualityStocks
Pharmacopeia, Inc. (NASDAQ: PCOP)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Onar Holding Corporation (OTCQB: ONAR) Details Board Additions, AI Partnerships and M&A Moves
Onar (OTCQB: ONAR), a marketing technology company and global network of performance-driven agencies, issued a…
-
QualityStocksNewsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Sees 504% Boat Sales Surge, Slashes Debt Following Nautical Ventures Acquisition
Vision Marine Technologies (NASDAQ: VMAR), a leader in electric marine propulsion and multi-brand boat…
-
Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Secures $18.4M DoD Award to Fast-Track Heavy Rare Earth Independence
This phase 2 award builds on phase 1 success, during which Ucore successfully separated two heavy…